Top 5 Movers of the Day – $BGM Rises Over 30% on Acquisition News

As of November 29, U.S. markets are showing modest gains. The Dow Jones is up 0.4%, the S&P 500 is also slightly higher, and the Nasdaq is leading with nearly a 1% increase. Market sentiment remains positive, driven by favorable economic data in recent weeks. While there’s no major economic data release today, investors are focused on the Fed’s monetary policy outlook and corporate earnings, both of which continue to provide support. $SPDR S&P 500 ETF (SPY.US)$ $Invesco QQQ Trust (QQQ.US)$

$BGM Group (BGM.US)$ – Up over 20%.
Global pharmaceutical leader BGM Group Ltd. (NASDAQ: BGM) announced it’s acquiring AIX Inc. (NASDAQ: AIFU) for 1 billion RMB (around $140M). The deal includes AIX’s subsidiaries, Rongsi Intelligent Technology (Beijing) Co., Ltd. and Shenzhen Xinbao Investment Management Co., Ltd. The transaction is expected to close by the end of 2024.
This strategic acquisition marks BGM’s official entry into AI tech and fintech services, diversifying its business beyond biopharma and setting the stage for its digital transformation.

$Unusual Machines (UMAC.US)$ – Up over 40%.
UMAC, a drone and components manufacturer, is benefiting from structural changes in the U.S. drone market. Recent private equity raises have provided the company with funding for expanded production and R&D. Additionally, its active participation in industry investment conferences is boosting investor confidence in its growth potential. The stock surged further after Donald Trump Jr. was announced as a member of the company’s advisory board.

$SOS Ltd (SOS.US)$ – Up over 30%.
SOS shares jumped sharply, driven by a recovery in the blockchain sector. The company’s board recently approved a $50 million investment to purchase Bitcoin, adding to its bullish momentum.

$Alterity Therapeutics (ATHE.US)$ – Up over 30%.
ATHE is making strides in developing innovative treatments for neurodegenerative diseases like Parkinson’s. Progress in its pipeline has investors excited about its potential profitability. Anticipation of FDA approval for its new drug is fueling the stock’s rally.

$Klotho Neurosciences (KLTO.US)$ – Up over 80%.
KLTO’s massive surge is linked to breakthroughs in neuroscience technology, particularly in treating cognitive impairments. Recent product announcements and positive market feedback have strengthened investor confidence in its growth trajectory.